Get 40% Off
☕ Buy the dip? After losing 17%, Starbucks sees an estimated 20% upside. See the top Undervalued stocks!Unlock list

LyondellBasell (LYB) Unveils Preliminary Guidance For Q2

Published 06/26/2019, 09:32 PM
Updated 07/09/2023, 06:31 AM

LyondellBasell Industries N.V. (NYSE:LYB) provided a preliminary guidance for second-quarter 2019 financial results.

For the second quarter, the company expects EBITDA to improve roughly 10-20% sequentially to the range of $1,575 million-$1,675 million. Net income is projected between $1,035 million and $1,080 million. Earnings per share (EPS) is forecast to be between $2.79 and $2.91.

The company stated that North American integrated ethylene margins improved during the second quarter courtesy of lower feedstock costs. Moreover, oxyfuels are witnessing typical seasonal upside. However, margins in the refining business continues to be a headwind.

Notably, the company is providing guidance on a one-time basis related to the tender offer for its ordinary shares that started on Jun 10, 2019 and is slated to expire on Jul 8, 2019.

Shares of LyondellBasell have lost around 21.1% in the past year compared with the industry’s 33.9% decline.


LyondellBasell is on track with the construction of a HDPE plant on the U.S. Gulf Coast that will employ its proprietary Hyperzone PE technology. The facility is scheduled for startup in third-quarter 2019 and will have an annual capacity of 1.1 billion pounds.

Moreover, the A. Schulman buyout doubles the size of LyondellBasell's existing compounding business. It has also created a platform for future growth and enabled the company to reach into additional high-growth markets such as packaging and consumer products, electronics and appliances, building and construction as well as agriculture.

Zacks Rank & Key Picks

LyondellBasell currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the basic materials space are Materion Corporation (NYSE:MTRN) , Flexible Solutions International Inc (NYSE:FSI) and AngloGold Ashanti Limited (NYSE:AU) . These stocks currently sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Materion has an expected earnings growth rate of 27.3% for 2019. The company’s shares have gained 20.1% in the past year.

Flexible Solutions has a projected earnings growth rate of 342.9% for the current year. The company’s shares have surged 143.2% in a year’s time.

AngloGold has an estimated earnings growth rate of 90.6% for the current year. Its shares have rallied 125.5% in the past year.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


LyondellBasell Industries N.V. (LYB): Free Stock Analysis Report

Flexible Solutions International Inc. (FSI): Free Stock Analysis Report

AngloGold Ashanti Limited (AU): Free Stock Analysis Report

Materion Corporation (MTRN): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.